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Spider venom administration
impairs glioblastoma growth and
modulates immune response in a
non-clinical model
Amanda Pires Bonfanti 1,2,9, Natália Barreto1,2,9, Jaqueline Munhoz1,2, Marcus Caballero1,2,
Gabriel Cordeiro1,2, Thomaz Rocha-e-Silva3, Rafael Sutti4, Fernanda Moura5, Sérgio Brunetto6,
Celso Dario Ramos 7, Rodolfo Thomé8, Liana Verinaud2 & Catarina Rapôso 1*
Molecules from animal venoms are promising candidates for the development of new drugs. Previous
in vitro studies have shown that the venom of the spider Phoneutria nigriventer (PnV) is a potential
source of antineoplastic components with activity in glioblastoma (GB) cell lines. In the present work,
the effects of PnV on tumor development were established in vivo using a xenogeneic model. Human
GB (NG97, the most responsive line in the previous study) cells were inoculated (s.c.) on the back of
RAG−/− mice. PnV (100 µg/Kg) was administrated every 48 h (i.p.) for 14 days and several endpoints
were evaluated: tumor growth and metabolism (by microPET/CT, using 18F-FDG), tumor weight and
volume, histopathology, blood analysis, percentage and profile of macrophages, neutrophils and NK
cells isolated from the spleen (by flow cytometry) and the presence of macrophages (Iba-1 positive)
within/surrounding the tumor. The effect of venom was also evaluated on macrophages in vitro. Tumors
from PnV-treated animals were smaller and did not uptake detectable amounts of 18F-FDG, compared
to control (untreated). PnV-tumor was necrotic, lacking the histopathological characteristics typical of
GB. Since in classic chemotherapies it is observed a decrease in immune response, methotrexate (MTX)
was used only to compare the PnV effects on innate immune cells with a highly immunosuppressive
antineoplastic drug. The venom increased monocytes, neutrophils and NK cells, and this effect was the
opposite of that observed in the animals treated with MTX. PnV increased the number of macrophages
in the tumor, while did not increase in the spleen, suggesting that PnV-activated macrophages
were led preferentially to the tumor. Macrophages were activated in vitro by the venom, becoming
more phagocytic; these results confirm that this cell is a target of PnV components. Spleen and in
vitro PnV-activated macrophages were different of M1, since they did not produce pro- and antiinflammatory cytokines. Studies in progress are selecting the venom molecules with antitumor and
immunomodulatory effects and trying to better understand their mechanisms. The identification,
optimization and synthesis of antineoplastic drugs from PnV molecules may lead to a new multitarget
chemotherapy. Glioblastoma is associated with high morbidity and mortality; therefore, research to
develop new treatments has great social relevance. Natural products and their derivatives represent
over one-third of all new molecular entities approved by FDA. However, arthropod venoms are
underexploited, although they are a rich source of new molecules. A recent in vitro screening of the
Phoneutria nigriventer spider venom (PnV) antitumor effects by our group has shown that the venom
significantly affected glioblastoma cell lines. Therefore, it would be relevant to establish the effects
of PnV on tumor development in vivo, considering the complex neoplastic microenvironment. The
1

Faculdade de Ciências Farmacêuticas, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, UNICAMP, Campinas, SP, Brazil. 3Faculdade
Israelita de Ciências da Saúde Albert Einstein, São Paulo, SP, Brazil. 4Faculdade de Ciências Médicas, Santa Casa
de São Paulo, São Paulo, SP, Brazil. 5Faculdade de Ciências Médicas, UNICAMP, Campinas, SP, Brazil. 6Centro de
Engenharia Biomédica, UNICAMP, Campinas, SP, Brazil. 7Serviço de Medicina Nuclear, Hospital das Clínicas,
UNICAMP, Campinas, SP, Brazil. 8Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
9
These authors contributed equally: Amanda Pires Bonfanti and Natália Barreto. *email: raposo@unicamp.br
2

Scientific Reports |

(2020) 10:5876 | https://doi.org/10.1038/s41598-020-62620-9

1

www.nature.com/scientificreports/

www.nature.com/scientificreports

venom was effective at impairing tumor development in murine xenogeneic model, activating the
innate immune response and increasing tumor infiltrating macrophages. In addition, PnV activated
macrophages in vitro for a different profile of M1. These activated PnV-macrophages have potential
to fight the tumor without promoting tumorigenesis. Studies in progress are selecting the venom
molecules with antitumor and immunomodulatory effects and trying to better understand their
mechanisms. We aim to synthesize and carry out a formulation with these antineoplastic molecules
for clinical trials. Spider venom biomolecules induced smaller and necrotic xenogeneic GB; spider
venom activated the innate immune system; venom increased blood monocytes and the migration
of macrophages to the tumor; activated PnV-macrophages have a profile different of M1 and have a
potential to fight the tumor without promote tumorigenesis.
Glioblastoma (GB) is the most common and aggressive primary malignant brain tumor in adults, accounting for
more than half of malignant gliomas1. Although rare, they are associated with high morbidity and mortality, and
few patients achieve long-term survival of 2.5 years. The relative survival for the first year is 35%, 13.7% for the
second year and less than 5% surviving for 5 years after diagnosis2,3. A multimodal approach including maximal
surgical resection, radiotherapy and adjuvant chemotherapy with temozolomide or carmustine is the standard
therapy (for patients with newly diagnosed GB and younger than 70 years old)4. However, recurrence seems to
be the rule, despite the standard care. Notwithstanding efforts to find better treatment, it remains an incurable
disease with a poor survival rate.
Natural products have greatly contributed to the history of drugs development and identification of new
molecular entities. Patridge et al.5 assessed all FDA-approved new molecules, revealing that natural products
and their derivatives represented over one-third of those new entities. Nearly one-half of these are derived from
mammals, one-quarter from microbes and one-quarter from plants. On the other hand, the venoms of arthropods (mainly spiders and scorpions) are an underexploited source of new molecular entities. These venoms are
a mixture of biologically active molecules, such as proteins and non-protein substances, with specific targets in
cells and tissues6, representing promising compounds to guide the development of drugs. Hence, biomolecules
in scorpion and spider venoms have been shown to affect the cancer hallmarks (see Rapôso7 for a comprehensive
review).
The venom of the spider Phoneutria nigriventer (PnV) (Ctenidae, Araneomorphae), from South America, contains potent basic peptides, some of them neurotoxic8. PnV has been shown to permeate the blood–brain barrier
(BBB)9–12 and affect astrocytes, inducing profound alterations in their morphology and cytoskeleton13. Such data
opened room for the hypothesis that the venom could have molecular targets in glioma cells.
In fact, a recent in vitro screening of the PnV antitumor effects has shown that the venom is a potential source
of cancer drug candidates14. The venom significantly affected all of the tumor cell lines studied, although the
non-glioma tumor cell (HeLa – cervical tumor line) was less sensitive than GB cell lines (NG97 and U-251). A
clinically relevant point is that the venom had no cytotoxic effect on non-tumor cells (fibroblasts L929 line). In
the present study, the effects of PnV on tumor development were established in vivo, in addition to analyzing the
innate immune response and the prognosis, using a xenogeneic murine model.

Materials and Methods

Reagents and venom. All the chemicals were obtained from Sigma Aldrich (St. Louis, MO), unless other-

wise stated. Two samples of crude lyophilized venom of P. nigriventer were obtained by electrical stimulation of
numerous adult spiders (male and female). The quality and reproducibility of the venom were evaluated by high
pressure liquid chromatography (HPLC) in a reverse phase C18 column monitored at 214 nm. The lyophilized
venom was stored at −80 °C and dissolved immediately prior to use.

Animal care, tumor implant and treatments. All experiments were conducted in accordance with the
Ethical Principles on Animal Research, adopted by the Brazilian College on Animal Experimentation (Colégio
Brasileiro de Experimentação Animal – COBEA), with the prior approval of the Ethics Committee on the Use of
Animals (CEUA) of the Universidade Estadual de Campinas (UNICAMP) (#4603-1/2017). The use of Genetically
Modified Organism (GMO) was authorized by the Internal Biosafety Committee of UNICAMP (CIBio)
(#2017/02). The animals were kept in the Animal Facility of the Biology Institute, Department of Functional and
Structural Biology, UNICAMP.
Immunodeficient C57BL6 RAG−/− (B6.129S7-Rag1tm1Mom) mice, females, 8 to 12 weeks old, were used to
perform the dorsal subcutaneous xenogeneic tumor model. Human glioblastoma NG97 cells were donated by a
patient from the Hospital of the UNICAMP and the cell line was established and characterized in a sequence of
published studies15–19. 3 × 105 cells were suspended in 100 μL of PBS and injected subcutaneously into the dorsal
flank of mice. After 7 days of cells inoculation, the animals were randomly divided into three groups (n = 6–8 per
group): control (treated with 100 μL sterile 0.9% saline – vehicle – intraperitoneal every 48 hours), PnV (treated
with venom, 100 µg/Kg in 100 µL, intraperitoneally every 48 hours) and MTX (treated with methotrexate, 5 mg/
Kg in 100 µL, intramuscularly every 48 hours; this group was made only to compare the blood parameters). The
treatments were performed for 14 days; therefore, the total duration of the experiment was 21 days. Throughout
the experiment, the animals were monitored daily for body weight and survival. At the end, mice were euthanized
and the tumors were excised for weight and volume recording and other analysis described below.
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Micro PET-CT (Positron Emission Tomography and Computed Tomography). The micro-PET/
CT scan (AlbiraSi, Bruker) was performed on the day 21 (at the end of the treatments), at the Preclinical Image
Laboratory (LIP) - Medical Sciences School, UNICAMP. The equipment has three attached image modes: PET,
SPECT and CT. For this research, the PET and CT modalities were used. Prior to administration of the radiotracer 18F-FDG (fluorodeoxyglucose), mice were fasted for at least 6.0 h. The 18F-FDG was injected into the
intraorbital plexus (i.v.) 40 min before the scan start, for the biodistribution of the radiotracer. The animal was
placed in a dedicated isoflurane administration system (MIP/Anesthesia Technologies) for inhalation anesthesia.
With no further motor stimuli, the radiotracer was administered and throughout the experiment the animal
was maintained under isoflurane and oxygen administration. In addition, the temperature of the animal’s environment was constantly checked, reaching about 23 °C (73.4 °F). The protocols chosen (selected) to acquire the
images of the animals were: PET in single mode of 20 minutes and CT of 35 kV, 400 uA and 1024 projections. The
images were reconstructed in the AlbiraSi system reconstruction mode. For CT, two images were generated: CT
Low (for attenuation correction) and CT High (for corregistration and fusion). For PET, the MLEM (Maximum
Likelihood Estimation Method), with voxel size 20 × 20 × 0.5, 12 iterations and with all the corrections activated
(scatter correction, decay correction and attenuation correction with CT Low), was used. Finally, for the quantification of the images, the PET fusion image with attenuation correction and CT High were used. To quantify
the uptake of the radiotracer present in the volume, the SUV calculation (standardized uptake value) is adopted.
This metric can be defined as the ratio between the concentration of activity present in the structure (Bq/volume)
and the activity injected (Bq) in the individual multiplied by its respective mass (grams for animals and kilograms
for humans). In the present work, the SUV average was quantified, that is, the value of the average concentration
present in the structure of interest.
Tumor histopathology.

After PET-CT, the animals were anesthetized with ketamine (80 mg/Kg) and
xylazine (10 mg/Kg) and sacrificed. The tumors were dissected and fixed in phosphate-buffered 10% formalin.
Samples were then dehydrated by graded ethanol and embedded in Paraplast Plus. Sections of 5 µm were examined after staining with hematoxylin and eosin (H&E).

Blood analysis – blood cells and toxicity-related parameters. After euthanasia, blood was collected

for hemogram and serum was used for determination of markers of hepatic dysfunction (glutamic-oxaloacetic
transaminase – GOT; and glutamic pyruvic transaminase – GPT) and renal dysfunction (creatinine and urea).
Blood tests were performed by a specialized veterinary laboratory (Echoa Laboratory, Campinas, SP, Brazil).

Flow cytometry of circulating immune cells. The spleen was collected from all mice to evaluate macrophages, neutrophils and natural Killer (NK) surface proteins and cytokines expression. Spleens were individually homogenized in 1 mL of sterile PBS (0.02 M phosphate buffered saline) using 70 µm cell strainer. After
viability testing with Trypan Blue, the cells were incubated with PMA (Phorbol 12-myristate 13-acetate, 1 mg/
mL), Ionomycin (5 mg/mL) and Brefeldin A (5 mg/mL) for 4 h, at 37 °C, and the immunostaining was done with
the following antibodies (all from eBioscience, USA): anti-CD11b (Clone M1/70, PE, #557397) and anti-F4/80
(Clone BM8, PE-Cy7, #25-4801-82), incubated for 30 minutes (4 °C, in a dark chamber) (anti-Ly6G/Ly6C Clone
RB6-8C5, PE, #553128, and anti-NK1.1 Clone PK136, PE, #553165 were also done and are available in the
Supplemental Material). The cells were then fixed with 1% paraformaldehyde and permeabilized with specific
buffer. After, cells were incubated with antibodies against the cytokines: IFN-γ (Clone XMG1.2, APC, #126406)
and IL-10 (Clone JES5-16E3, PerCP Cy5.5, #505028) (overnight, at 4 °C, in dark chamber). Cells were acquired
using flow cytometer and data were analyzed by FlowJo VX software.
Immunofluorescence: detection of tumor associated macrophages. The level of Iba-1 (a macrophage marker) was investigated in 5 μm paraffin sections. Sections were deparaffinized and boiled in citrate
buffer (1 mM; pH 6.0) for 30 min in a steam cooker for antigenic recovery. Rabbit polyclonal antibody against
Iba-1 (1:100 dilution, FUJIFILM Wako Chemicals U.S.A Corp, Richmond, VA, EUA, #019-19741) was used as
primary antibody (negative controls were maintained in PBS), followed by secondary anti-rabbit Cy5 conjugated
(Jackson Immuno Research, #711-175-152). Images were acquired using a microscope (Leica DM5500B) coupled
to a camera (DFC345 FX) and Image-ProPlus 6.0 software (Media Cybemetics, USA).
Cell culture and treatments.

Macrophages were obtained from differentiation of murine bone marrow
cells cultivated with L929 cells supernatant, according to Marim et al.20. Bone marrow precursors were collected
from femurs of 7–10 weeks old male C57BL/6 J mice. After collection, the marrow cell suspension was cultured
in Petri dishes with 10 mL of Iscove’s Modified Dulbecco’s Media (IMDM) supplemented with 20% fetal bovine
serum (FBS) and 30% L929 cell supernatant (as a source of M-CSF). After four days, another 10 mL of fresh
medium was added in the same proportions. This culture was incubated for seven days at 37 °C and 5% of CO2
and thereafter these cells were washed with PBS and adherent cells (differentiated macrophages) were harvested
with a cell scraper and transferred to a 24 wells plate (2 × 105 cells per well) with a round cover slip at the bottom.

Phagocytosis assay.

For this test, the pHrodo Red E. coli BioParticles Conjugate for Phagocytosis assay
was used (Thermo Fisher Scientific, #P35361). The macrophages were pre-activated with 20 ng/mL recombinant
mouse IFN-γ (BD #554587) for 48 h and then received the following treatments: PBS only (M0 profile control),
E. coli O26:B6 LPS 1 µg/mL (used as a canonical positive control of macrophages activation to M1 profile21 to
compare with PnV effects), or PnV 14 µg/mL. After 24 h, treatments were removed, macrophages were washed
with PBS and incubated for 4 h with 50 µg bioparticles. The cells were then extensively washed, fixed with paraformaldehyde for 15 min and labeled with Iba-1 by immunofluorescence. Briefly, cells were incubated with blocking buffer (PBS with 1% BSA and 0.3% Triton X100) for 2 h, followed by anti-Iba-1 (Wako #019-19741; 1:700)
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overnight, and secondary antibody (Cy2-Goat anti-rabbit, Jackson ImmunoResearch, #111225144; 1:1000) for
1 h. Nuclei were stained with DAPI (1:1000) for 5 min. Macrophages were washed and sliders were mounted using
a mounting medium for fluorescence. Images were acquired in the Cytation 5 – Cell Imaging Multi-Mode reader
(BioTek, Winooski, VT, USA). For quantification, images of three randomly selected fields per treatment were
taken and integrate analysis of pixels was determined using Image J software (version 1.52p, NIH, USA).

ELISA (enzyme-linked immunosorbent assay). The quantification of TNF-alpha and IL-10 in the cul-

ture medium was performed using R&D Systems – DuoSet immunoassay kits in accordance with the manufacturer’s instructions. Monoclonal antibodies specific for mouse TNF-alpha and IL-10 were pre-coated on the
microplate. Standards, controls and samples were pipetted into the wells and any TNF-alpha or IL-10 present was
bound to the immobilized antibody. Following washing, a substrate solution was added. The enzyme reaction
yields a blue product that turns yellow when the stop solution is added. The intensity of the color measured is in
proportion to the amount of mouse cytokines bound at the initial steps. The sample values were then read off the
standard curve in a Multiskan Go microplate spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA,
USA). All dosages were performed in triplicate.

Venom purification and MTT (cell viability assay). The initial fractionation of the crude venom was
performed by the Amicon Ultra Centrifugal Filter (#UFC801008; Thermo Fisher Scientific, Suwannee, GA). This
procedure consisted of separating crude venom by molecular mass using molecular filters, generating three main
fractions named: F1 (low weight, less than 3 kDa), F2 (intermediate weight, between 3 and 10 kDa) and F3 (high
weight, more than 10 kDa). From these, cell viability assay (MTT; described below) was conducted to select the
most significant fraction, considering the antineoplastic effects; Then, F1 and F2 were chosen and F3 was eliminated. Further purification of F1 and F2 was carried out: reversed phase HPLC was performed using a Shimadzu
VP-ODS column, 0.1% trifluoroacetic acid (TFA) as mobile phase and 90% acetonitrile 0.1% TFA as eluent. More
purified components were obtained, named subfractions 1–12 (SF1-SF12).
Thiazolyl Blue Tetrazolium Bromide (MTT) was used to determine if Fs and SFs would alter cell viability.
NG97 cells were seeded in 96-well plates at an initial density of 5 × 105 cells per well and incubated for 72 h at
37 °C for confluence (in IMDM supplemented with 10% FBS and 100 UI/ml penicillin and streptomycin). Then,
cells were treated with PnV (14 µg/ml), F1, F2, F3 or all twelve subfractions (SF1-SF12; 0.1 µg/ml) for 5 h, while
control cells were maintained in medium. After removal of the treatments, MTT was added to each well and
incubated at 37 °C for 4 h according to the manufacturer’s protocol. Thereafter, acidified isopropanol was added
to each well to solubilize the blue formazan crystals. Absorbance at 540 nm was determined on a Multiskan GO
spectrophotometer.
Statistic.

Values were analyzed using the GraphPad Prism software package (San Diego, CA, USA; v. 5.0).
The level of significance was obtained by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple
comparisons test. Error bars show the standard error of the mean (SEM). Unpaired Student’s t-test was used to
compare each treatment with the control. A p-value <0.05 indicated statistical significance.

Results

Quality and reproducibility of venom.

HPLC demonstrated that there was no significant difference
between the two extracted venom samples. The samples were the same used in the experiments published before
by Santos et al. [14], however the quality of PnV lots was established using 214 nm wavelength (Supplementary
Fig. 1).

PnV administration increased body weight gain and improved survival, compared to control. The control group recorded gradual loss of weight (data were not significant) after inoculation of the cells

(day 1) until the end of the experiment (day 20, last recorded weight). On day 7, the treatments were started. The
PnV group presented weight loss on day 7 in relation to day 1, followed by progressive recovery after the beginning of the treatment, being significant when comparing day 20 with day 7 (p < 0,05) (Fig. 1A). Control animals
showed 40% of mortality (due to general clinical condition caused by the tumor), while PnV group had no deaths
(Fig. 1B).

Mice treated with PnV developed smaller and 18F-FDG-negative tumors, compared to control
and MTX. Figure 1(C–G) shows representative animals (schematically and per photograph) of the control

(C and D) and PnV (E - G), at the end of the experiment (day 21). PET-CT images showed that control animals
developed large tumors (Fig. 2A,B,D), with intense uptake of 18F-FDG (Fig. 2C,E), suggesting a high metabolism,
expected for these tumor cells. Mice receiving PnV therapy showed smaller tumors (Fig. 2F,G,L), which were
negative for 18F-FDG (Fig. 2H,J), indicating slower metabolism compared to control. Figure 2A,B represent 3D
reconstructions of CT for each group. The graphs K and L of Fig. 2 show the statistic results of tumor weight and
volume, respectively, and graph M shows the results of 18F-FDG uptake (SUV average). Representative animals
of control and PnV groups are also shown by 3D animation. Table 1 shows the weight and volume of individual
tumors.
Supplementary Figure 2 shows a PnV-treated animal that did not develop tumor in the back (the site of cells
inoculation), however, interestingly, only this mouse developed a brain tumor, as shown by CT (B - D) and PET18
F-FDG (E - G) (panel A represents a 3D reconstruction).

Chemotherapy with PnV induced tumor necrosis. Histopathological analysis has showed that control animals developed tumors with typical GB characteristics (Fig. 3A–C). Panel A of Fig. 3 shows a hypercellular tumor composed of a variety of cell types (cell polymorphism) (asterisks), including small cells with
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Figure 1. Body weight variation and survival. (A) – The graph shows the average body weight gain in untreated
(control) and PnV-treated mice (red and black lines, respectively). The first weight (day 1) was considered zero
(no gain). After 7 days of cells inoculation, treatments were initiated (day 7). At day 21, PnV treated animals
significantly recovered the lost body weight, compared to day 7 (*P < 0.05). (B) – Graph showing the survive
during the experiment. The control group presented 40% mortality, whereas PnV treated group did not show
death (100% survival). (C–G) Schematic illustrations and photos of representatives RAG−/− mice with tumor
implanted into the back. (C,D) - Control animal (untreated) 21 days after inoculation of GB (NG97) cells,
showing a large tumor. (E,F) - PnV-treated animal 21 days after inoculation of GB (NG97) cells, showing a
smaller tumor; some PnV-treated animals did not develop tumor mass (G). Arrows in B and D indicate the
tumor.
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Figure 2. Positron Emission Tomography-Computed Tomography (PET-CT) 21 days after inoculation of
GB (NG97) cells. (A–E) Control animal (untreated). (F–J) PnV-treated animal. A and F are reconstructed 3D
images; (B–H) are sagittal sections; (D–J) are transversal sections. The tumor boundaries are surrounded by a
line. Only the PnV-treated animal was demonstrated by the CT and PET overlap, since there was no uptake of
18
F-FDG (panels H and J). Graphs K and L show, respectively, statistical analysis of tumor weight and volume
(measured after dissecting). Graph G shows 18F-FDG uptake (SUV - Standardized Uptake Value). **p < 0.01,
***p < 0.001.

hyperchromatic nuclei, cells with pink glial-like cytoplasm, and endothelial cells. In panel B, it is possible to see
an area with a pink cellular necrosis at the center (asterisk) with tumor cell palisading (arrow); also, glomeruloid
vascular proliferation of endothelial cells is present (arrow on panel C).
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Animal

Tumor weight (mg)

Tumor volume (mm3)

Control 1

582.7

15.8

Control 2

—

—

Control 3

434.1

22.1

Control 4

501.7

15.8

Control 5

556.1

35.8

Control 6

—

—

Control 7

459.2

35.7

Control 8

—

—

Control 9

472.0

44.2

Control 10

—

—

PnV 1

0.0

0.0

PnV 2

0.0

0.0

PnV 3

34.0

6.3

PnV 4

29.5

7.4

PnV 5

580.0

33.7

PnV 6

32.7

6.3

PnV 7

122.4

9.5

PnV 8

113.0

12.6

PnV 9

0.0

0.0

PnV 10

178.2

22.1

Table 1. Weight and volume of tumors. Four control animals died during the experiment and tumor data were
not considered.
Tumors of animals treated with PnV have lost most of the typical characteristics of glioblastoma; It has showed
many congestive blood vessels (arrow in panels D and E of Fig. 3) and large areas of necrosis (asterisks in panels
E and F).

Treatment with PnV altered blood cell count, leading to a different profile compared to
MTX. In general, chemotherapy with PnV induced an increase in blood cells, whereas MTX induced a

decrease (expected for traditional chemotherapy) (Fig. 4); The treatments did not significantly alter the total leucocytes, however it can be observed that, qualitatively, PnV-treated animals were prone to increase them, while
MTX showed a decrease (Fig. 4A). The same profile was observed for the number of neutrophils (Fig. 4B). The
percentage of cells, on the other hand, showed that PnV did not induce change, whereas MTX induced a significant neutropenia (Fig. 4C). Treatment with PnV induced a significant increase in the number of monocytes and
percentage of cells (compared to control and MTX) (Fig. 4D,E). For eosinophils, no significant alterations were
observed (Fig. 4F,G).
Compared to the control, PnV did not change the number of erythrocytes. However, the number of red cells
was significantly lower in the animals receiving MTX (Fig. 5A). A similar result was observed for hemoglobin
and hematocrit (Fig. 5B,C). PnV did not alter the platelets, comparing to the control animals. MTX, on the other
hand, induced a significant increase in platelets compared to all other groups (Fig. 5D).

Chemotherapy with PnV induced alterations in hepatic, but not in kidney, functional parameters. Hepatic function markers, GOT and GTP, were also measured in serum (Fig. 5E,F). PnV induced a

significant increase of GOT, compared to control, whereas MTX did not lead to alterations of this enzyme. The
level of GTP was not significantly altered by the drugs compared to the control, although the venom tended to
increase this marker. Markers of renal function, urea and creatinine, were measured (Fig. 5G,H, respectively); the
treatments did not induce alteration in the serum levels of these markers.

PnV did not change total macrophages from spleen, but decreased macrophages expressing
IFN-γ and IL-10. The venom increased spleen neutrophils and natural killer (NK) cells. The

percentage of total macrophages (CD11b and F4/80 positive cells) isolated from the spleen were not altered by the
treatment with venom, in comparison to the control group (data not shown). On the other hand, the percentage
of macrophages (CD11b and F4/80 positive) expressing IFN-γ (activated/proinflammatory) (Fig. 6A–D) was
strongly decreased by PnV therapy, compared to control. Interestingly, a similar result was observed for IL-10
expressing macrophages (suppressor/anti-inflammatory) (Fig. 6E–H). On the other hand, MTX had the opposite
effect, significantly increasing macrophages in both profiles.
Figure 7 shows that the treatment with PnV did not alter the percentage of neutrophils, compared to control
(histograms A–C, and graph D); however, the MFI (Mean Fluorescence Intensity) and cytospin (Fig. 7E,F, respectively) revelated that PnV induced a significant increase in neutrophils compared to control. Analysis of NK cells
(NK1.1 positive) showed that PnV increased the percentage cells, compared to control (Fig. 7F–H). MTX did not
change neutrophils and NK cells from spleen in comparison to untreated group.
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Figure 3. Histopathology – Representative tumor sections stained with hematoxylin and eosin. (A–C): Control
animal; (D–F): PnV-treated animal. Arrows and asterisks show typical characteristics of glioblastoma (see the
main text for details). Note the extensive necrosis on the PnV tumor (asterisks in panels E and F). All figures
have the same scale (bar shown in panel A only).

Figure 4. White blood cell count. (A) - Treatments did not significantly alter the number of total leucocytes.
(B,C) - The number of neutrophils per mm3 was not significantly changed (B), however MTX significantly
decreased the cell percentage (C). (D,E) - PnV significantly increased the number of monocytes per mm3
(D) and percentage (E). The treatments did not altered eosinophils counts (F,G). *p < 0.05, **p < 0.01,
***p < 0.001.

Treatment with PnV increased the number of tumor associated macrophages (TAMs). Analysis

of Iba-1 positive cells (a macrophage marker) within and around the tumor mass revealed that in the control
tumor there were no macrophages (Fig. 8A–C). However, in the PnV treated mice, a large number of positive
cells was present in the surrounding tissue, in the periphery of the tumor and within the tumor mass (Fig. 8D–F).

In vitro macrophages were activated by PnV.

Fluorescent bioparticle phagocytosis assay (Fig. 9)
showed that venom-treated macrophages (panels C, F and I) were more activated than untreated cells (panels A,
D and G); LPS, used as a canonic positive control of macrophages activation to M1 profile, also induced increased
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Figure 5. (A–D) Red blood cell and platelet count. Red blood cells (A) hemoglobin (B) and hematocrits (C)
were significantly decreased in animals receiving MTX, compared to mice treated with PnV. The administration
of MTX significantly increased platelets compared with all other groups (D). (E–H) Serum dosage of renal (urea
and creatinine) and hepatic (GOT and GPT) functional markers. (E,F) – There were no significant changes in
urea and creatinine dosages. (G,H) – PnV significantly increased GOT, comparing to control, but GPT was not
altered by the treatments. *p < 0.05, **p < 0.01.

phagocytosis (panels B, E and H), however cells treated with PnV were even more active (See graph J in Fig. 9).
Figure 9 shows Iba-1 labeled cells (panels A–C), fluorescent bioparticles (panels D–F) and Iba-1/bioparticles/
DAPI merged images (G–I). ELISA measures (graphs K and L in Fig. 9) demonstrated that while LPS induced
increased TNF-alpha and IL-10 release, as expected, PnV did not change these cytokines.
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Figure 6. Flow cytometry of activated (F4/80+ and IFN-γ+) and suppressor (F4/80+ and IL-10+) macrophages
isolated from the spleen. (A–C) Representative histograms of activated macrophages. (E–G) Representative
histograms of suppressor macrophages. (D–H) – Graphs showing statistical analysis. PnV administration
decreased the percentage of both macrophage profiles compared to control, while MTX increased them.
*p < 0.05, ***p < 0.001.

Several subfractions obtained from PnV have cytotoxic effect on GB cells. The cell viability assay,

showed in Fig. 10A, demonstrated that F1 and F2 (low and intermediate wight components) were cytotoxic to
NG97 cells (F2 had statistical significance). F3 had no effects on GB cells. From the three tested concentrations,
0,1 µg/mL was the most significant. SF1-SF12, from F1 and F2 purification, were tested only at the concentration
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Figure 7. Flow cytometry of neutrophils (Ly6+) and Natural Killer cells (NK1.1+). (A–C): Representative
histograms of neutrophils. (D,E) – Graphs showing statistical results; PnV treatment did not change the
percentage of cells (D), however increased the MFI (mean fluorescence intensity) (E), compared to control. (F)
– Graph showing the results of cytospin; PnV induced a significant increase in the percentage of neutrophils,
compared to the control. (G–I) Representative histograms of NK cells. (J) – Graph showing statistical results;
PnV significantly increased the percentage of NK cells, compared to control. MTX did not change neutrophils
and NK cells in comparison to control cells. *p < 0.05, **p < 0.01.
of 0,1 µg/mL (Fig. 10B) and showed that only SF1 and SF12 had no effected on the viability of cells, comparing
to control. Nine subfraction, SF2-SF11, demonstrated anti-tumor effect, being the SF6, SF10 and SF11 the most
effective comparing to control cells.

Discussion

Recently, our group showed that P. nigriventer spider venom is cytotoxic to tumor cells in vitro, especially for
NG97 GB cell line7,14. As follows, in the present work we aimed to investigate whether the systemic administration of the venom would alter the development of xenogeneic GB (NG97) implanted in mice. Females were used
because the tumor development was more uniform than in males. The reason for this is unclear. The dose of PnV
was chosen after preliminary tests, where other doses (850, 500, 200, 100 and 50 µg/Kg) were tested. Previous
studies have shown that 850 µg/Kg was a sublethal dose in rats, however promoting several signs of intoxication
(limb paralysis, convulsion, tremors, sialorrhea, sometimes death). For this study, the highest dose among the five
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Figure 8. Immunostaining of the macrophage marker (Iba-1) in tumor sections. (A–C) Sections of a control
(untreated) animal. (D–F) Mouse treated with PnV. Note that the control group did not show Iba-1-positive
cells. On the other hand, sections of the PnV-treated animal have a large number of macrophages. All figures
have the same scale (bar shown in panel A only).

Figure 9. Phagocytosis assay using red E. coli pHrodo bioparticles; Immunofluorescence for Iba-1 (green) was
used as a macrophage marker and the nuclei were stained with DAPI (blue). (A,D and G) Control (untreated
cells) showed very little phagocytic activity; B - I: LPS and PnV treatments stimulated phagocytosis compared
to control. Graph J shows the fluorescence quantification and statistical analysis. ELISA quantifications are
demonstrated in graphs K and L. LPS induced increased amounts of TNF-alpha and IL-10, while PnV did not
alter these cytokines compared to control. All figures have the same scale (bar shown in panel A only).
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Figure 10. Cell viability assay (MTT). Graph A shows the effects of PnV (14 and 280 µg/mL) and three
venom fractions (F1, F2 and F3: < 3, between 3 and 10 and> 10 KDa, respectively; 0.1, 1 and 10 µg/mL) on GB
(NG97) cells in vitro. F1 and F2 at 0.1 µg/mL were more effective in decreasing cell viability, while F3 had no
effect. Graph B shows subfractions (SF1-SF12; 0.1 µg/mL) isolated from F1 and F2. Except SF1 and SF12, all
subfractions decreased cell viability, with SF6, SF10 and SF11 being the most significant.

tested, which did not cause any clinical signs of intoxication in any animal, was chosen (100 µg/Kg). In addition,
methotrexate (MTX) is a chemotherapeutic drug used to treat various types of cancer22; Although not used for
GB because the drug does not cross the BBB23, it is a classic chemotherapy that induces immunosuppression.
Therefore, in this work, MTX was used as a control only to compare with the effects of PnV in relation to the
effects on the immune cells.
The results demonstrated that PnV chemotherapy arrested tumor development. In addition, PnV tumors did
not uptake detectable amounts of 18F-FDG, suggesting impairment of the metabolism of tumor cells. High glucose uptake is a hallmark of cancer; FDG uptake was thought to indicate the aggressiveness of tumors and SUV
is a well-known measure for FDG uptake in PET/CT24. Therefore, the lower uptake of FDG may indicate that the
tumors of PnV treated animals were less aggressive compared to control.
It is relevant to report that in this study only one animal treated with PnV, instead of developing a tumor in
the back (site of inoculation of glioma cells), developed a tumor mass in the brain. This was a unique case and the
cause is unclear. However, the possibility that this may have happened because PnV is able to permeabilize the
BBB has to be considered for future therapeutic use of molecules obtained from the venom, since metastasis can
be facilitated by the opening of the barrier. In addition, previous studies have shown that, although the venom
promotes BBB breakdown in specific regions, changes in cell morphology or necrosis were absent in the central
nervous tissue25. On the other hand, PnV stimulates neurons and glia13,26, which may be related to the seizures
observed in envenomed rats and humans. An important observation is that, with the dose used in this study, the
mice did not present convulsion or any signs of intoxication. Nevertheless, venom is a mixture of molecular entities, and that with antineoplastic effects are hopefully to be different from those with target in the BBB, neuron
and glia; therefore, when the molecules have been isolated, these aspects have to be examined and the effects are
expected to be more specific towards cancer cells.
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Along with decreased tumor development, a better prognosis was observed in mice treated with PnV; the
animals presented lower mortality in relation to the control and better recovery of weight. Nevertheless, PnV
administration increased GOT levels in the serum, a marker of hepatic dysfunction. As same as before, we expect
that purification of tumor active molecules may abolish hepatotoxic effect.
Histopathology showed that animals from control group had polymorphic hypercellular tumors, as expected.
Other typical features were also present in this group, such as vascular proliferation, necrosis (with tumor cell palisading) and more than one cell type27,28. However, the majority of the tissue area in the PnV tumor was necrotic,
lacking the histopathological characteristics typical of GB. This may explain the low uptake of 18F-FDG in PnV
tumors.
To assess the systemic effects of venom, blood cells were analyzed, showing that PnV increased monocytes
and did not change neutrophils. This effect is different from that observed in classical chemotherapies, which
induce a decrease of immune cells. In the present study, MTX was used only to compare the effects of PnV with a
classical immunosuppressor chemotherapeutic drug. MTX induced a neutropenia, as expected, while it did not
affect monocytes. It is reported that MTX can affect hematopoiesis, causing leukopenia, anemia, and/or thrombocytopenia29. Corroborating with the literature, it was shown here that while PnV did not alter erythrocytes,
hemoglobin and hematocrits levels, in animals treated with MTX all these parameters were reduced. On the other
hand, while PnV did not change platelets count, MTX treatment increased. The literature often reports a decrease
in platelets (thrombocytopenia)22 induced by MTX; however, thrombocytosis developed due to the use of MTX
or MTX combined with other drugs has already been described30–32.
Considering the alterations induced by PnV in the blood immune cells, we decided to examine the profile of
the immune cells isolated from the spleen. Interestingly, PnV did not change total macrophages, while decreased
activated (IFN-γ positive) and suppressive (IL-10 positive) cells. Although PnV have decreased the percentage of
activated and suppressors macrophages isolated from the spleen, many macrophages were detected in the tumor
of animals treated with the venom, whereas they were not observed in the control. These results suggest that PnV
induced an increase in blood monocytes, and these cells were directed preferentially to the tumor. Hypoxia is a
common characteristic of many solid tumors and limited oxygen diffusion generates a gradient of oxygen availability from the blood vessel to the interstitial space and may underlie macrophages recruitment, promoting cancer
progression33. The macrophages can be recruited to the tumor in PnV-treated animals because the tumor is highly
necrotic and the environment is probably very poor of oxygen.
Macrophages in the tumor are known as Tumor Associated Macrophages (TAMs); TAMs exist in a spectrum,
exhibiting spatiotemporal plasticity in regard to the phenotype34,35. In a simplified way, these cells can be divided
into two subtypes, M1 and M2. Canonically, M1 is associated with pro-inflammatory properties and has antitumor effects, while M2 is associated with anti-inflammatory properties and promotes tumor growth and resistance
to therapy36. Nevertheless, increasing evidence suggests that both contribute to the tumorigenesis and tumor cell
migration/metastasis37. TNF-alpha and IL-12 are cytokines able to characterize M1, whereas IL-10 and IL-4 are
able to characterize M2 phenotype35,38. Considering that PnV induced a decrease in polarized macrophages, both
activated (INF-γ positive) and suppressed (IL-10 positive), it is possible that the profile of PnV-macrophages are
phenotypically different of typical TAMs (M1 and M2) and may be more effective in fighting the tumor without
promoting tumorigenesis.
It is important to mention that RAG−/− mice do not have the complete immune response (lacking T lymphocytes) and the immunomodulatory effects of PnV on other systems need to be tested. Therefore, to confirm and
better understand the effects of the venom, cultured macrophages generated from mice bone marrow were treated
with PnV. The venom activated the cells, which became more phagocytic than control (untreated). LPS, used as
a positive control of M1 induced profile21, also increased phagocytosis. On the other hand, while LPS enhanced
TNF-α and IL-10 cytokines release, as expected39, PnV-phagocytic macrophages did not produce those pro- or
anti-inflammatory cytokines, corroborating the in vivo findings. The PnV-activated macrophages profile seems
to be different of M1 or M2 phenotype. The effects of PnV and its molecules in the immune system needs to be
better investigated; experiments in immunocompetent mice and in a 3D spheroid coculture system are in course.
A previous report40 showed that P/Q- and N-type voltage-gated calcium channels (VGCC) inhibitors PhTx3-3
and Phα1β, from PnV, have inhibitory effects on proliferation and viability and evoked cell death of glioma cell
lines (M059J, U138MG and U-251MG). Furthermore, Phα1β caused significant reduction of tumor areas in vivo
and this toxin also increased GFAP-activated astrocytes and Iba-1 positive microglia in the peritumoral region,
showing a modulation of these immune cells, which corroborates current findings. It has been shown here that
purified fractions and subfractions of the PnV have antitumor action, decreasing the viability of GB cells; therefore, it is probable that not only calcium channel inhibitors are active in GBs. It is important to mention that the
cytotoxic effect of PnV and most SFs, although significant, was not very pronounced. Our hypothesis is that this
effect is added to the immunological activation against the tumor, resulting in a synergistic therapeutic action,
justifying the strong tumor reduction observed in this study in the in vivo model. We are isolating and characterizing the immunomodulatory and antitumor PnV molecules. In addition, components of the venom with
anti-migratory effects in GB cells are being identified.
In conclusion, the venom was effective in impairing tumor development in a murine xenogeneic model. It
has also been demonstrated for the first time that the venom has immunomodulatory effects, and this may be an
essential mechanism of the antineoplastic role of the venom components. The effects of PnV on immune cells
suggest that its components did not induce immunosuppression, like classical chemotherapeutic drugs. In addition, PnV treatment increased macrophages into and surround the tumor, however with a different profile of M1.
Studies in progress are selecting the venom molecules with antineoplastic and immunomodulatory effects and
trying to better understand their mechanisms. The identification and synthesis of antineoplastic/immunomodulatory molecules can lead to a new multitarget chemotherapy.
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